Fig. 1

ACAT2 expression level was detected by bioinformatics analysis, qRT-PCR and western blotting in ovarian cancer cell lines and stained by immunohistochemistry with anti-ACAT2 antibody in ovarian cancer tissues. (a) The cisplatin dose-response curve in A2780 and A2780/DDP cells. They were exposed to DDP with different concentrations (0, 0.25, 0.5, 1.0, 2.0, 4.0, 8.0, 16.0, 32.0 ug/mL) for 48 h. Cell viability was measured by CCK8. (b) Semi-quantitative analyses of the half inhibition rate of A2780 and A2780/DDP. (c-e) The relative ACAT2 mRNA expression level in A2780 and A2780/DDP from GSE 15709 and GSE 33482 (data normalization processing), and in OVCAR8 and OVCAR8/DDP from GSE 45553. (f) The relative expression level of ACAT2 mRNA in A2780 and A2780/DDP. It was indicated as a normalization of GAPDH in each sample to the control. (g) The western blotting of ACAT2 in A2780 and A2780/DDP cells. GAPDH was used as the endogenous reference. (h) The relative expression level of ACAT2 protein was indicated as a normalization of GAPDH in each sample to the control. (i) ACAT2-low expression in platinum-sensitive (x100); (j) ACAT2-low expression in platinum-sensitive (x400); (k) ACAT2-high expression in platinum-sensitive (x100); (l) ACAT2-high expression in platinum-sensitive (x400); (m) ACAT2-low expression in platinum-resistant (x100); (n) ACAT2-low expression in platinum-resistant (x400); (o) ACAT2-high expression in platinum-resistant (x100); (p) ACAT2-high expression in platinum-resistant (x400). (q) Immunohistochemical semi-quantitative scores of ACAT2 expression in OC tissues